150 related articles for article (PubMed ID: 2540251)
1. Immunized mice challenged with herpes simplex virus by the intranasal route show protection against latent infection.
Rooney JF; Wohlenberg C; Cremer KJ; Notkins AL
J Infect Dis; 1989 May; 159(5):974-6. PubMed ID: 2540251
[No Abstract] [Full Text] [Related]
2. Herpes simplex virus type 1-vaccinia virus recombinant expressing glycoprotein B: protection from acute and latent infection.
Willey DE; Cantin EM; Hill LR; Moss B; Notkins AL; Openshaw H
J Infect Dis; 1988 Dec; 158(6):1382-6. PubMed ID: 2848904
[No Abstract] [Full Text] [Related]
3. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted.
Farrell HE; McLean CS; Harley C; Efstathiou S; Inglis S; Minson AC
J Virol; 1994 Feb; 68(2):927-32. PubMed ID: 8289395
[TBL] [Abstract][Full Text] [Related]
4. Latent infection of sensory ganglia with herpes simplex virus: efficacy of immunization.
Price RW; Walz MA; Wohlenberg C; Notkins AL
Science; 1975 May; 188(4191):938-40. PubMed ID: 166432
[TBL] [Abstract][Full Text] [Related]
5. Latent HSV-1 infection in mice immunized with a zwitterionic detergent-extracted HSV-1 antigen preparation.
al-Ghamdi A; Jennings R; Bentley H; Potter CW
Arch Virol; 1989; 108(1-2):19-31. PubMed ID: 2556982
[TBL] [Abstract][Full Text] [Related]
6. Restriction of latent herpes virus infection in rabbits immunized with subviral herpes simplex virus vaccine.
Rajcáni J; Kutinová L; Vonka V
Acta Virol; 1980 May; 24(3):183-93. PubMed ID: 6107035
[TBL] [Abstract][Full Text] [Related]
7. Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes.
Manickan E; Rouse RJ; Yu Z; Wire WS; Rouse BT
J Immunol; 1995 Jul; 155(1):259-65. PubMed ID: 7602102
[TBL] [Abstract][Full Text] [Related]
8. Expression and stability of herpes simplex virus antigens in Salmonella typhimurium.
Bowen JC; Reddy RM; Alpar HO; Brown MR; Rouse BT
Adv Exp Med Biol; 1995; 371B():1543-6. PubMed ID: 7502853
[No Abstract] [Full Text] [Related]
9. Protection of mice against lethal challenge with herpes simplex virus by vaccination with an adenovirus vector expressing HSV glycoprotein B.
McDermott MR; Graham FL; Hanke T; Johnson DC
Virology; 1989 Mar; 169(1):244-7. PubMed ID: 2538036
[TBL] [Abstract][Full Text] [Related]
10. Protection from oral herpes simplex virus infection by a nucleic acid-free virus vaccine.
Kitces EN; Morahan PS; Tew JG; Murray BK
Infect Immun; 1977 Jun; 16(3):955-60. PubMed ID: 197013
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with herpes simplex virus type 1 glycoprotein K impairs clearance of virus from the trigeminal ganglia resulting in chronic infection.
Ghiasi H; Cai S; Nesburn AB; Wechsler SL
Virology; 1996 Oct; 224(1):330-3. PubMed ID: 8862430
[TBL] [Abstract][Full Text] [Related]
12. Effect of immunization on the development of latent ganglionic infection in mice challenged intravaginally with herpes simplex virus types 1 and 2.
Asher LV; Walz MA; Notkins AL
Am J Obstet Gynecol; 1978 Aug; 131(7):788-91. PubMed ID: 210669
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulation of experimental murine herpes simplex keratitis: I. UV-HSV protection.
Thompson P; Wells PA; Sandstrom IK; Opremcak EM; Millin JA; Daigle JA; Foster CS
Curr Eye Res; 1988 Nov; 7(11):1043-9. PubMed ID: 2854036
[TBL] [Abstract][Full Text] [Related]
14. Expression of herpes simplex virus 1 glycoprotein B in human cells and protection of mice against lethal herpes simplex virus 1 infection.
Manservigi R; Negrini M; Gualandri R; Milanesi G; Barbanti-Brodano G
Adv Exp Med Biol; 1989; 257():263-71. PubMed ID: 2559611
[No Abstract] [Full Text] [Related]
15. Herpes simplex virus vaccines.
Meignier B; Roizman B
Antiviral Res; 1985; Suppl 1():259-65. PubMed ID: 3002260
[No Abstract] [Full Text] [Related]
16. Protection against establishment of latent infections in mice immunized with a non-pathogenic herpes simplex virus mutant and reinfected with the pathogenic parental strain.
Klein RJ; Kaley LA; Friedman-Kien AE
Vaccine; 1984 Sep; 2(3):219-23. PubMed ID: 6099650
[TBL] [Abstract][Full Text] [Related]
17. Prospects for vaccination against herpes simplex virus.
Whitley RJ
Pediatr Ann; 1993 Dec; 22(12):726, 729-32. PubMed ID: 8139874
[No Abstract] [Full Text] [Related]
18. Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1.
Morrison LA; Knipe DM
Virology; 1997 Dec; 239(2):315-26. PubMed ID: 9434723
[TBL] [Abstract][Full Text] [Related]
19. Establishment of latent ganglionic infection with herpes simplex virus via maxillary gingiva and viral re-activation in vivo after trauma.
Shimizu F; Monma Y; Sekizawa T; Kamiyama K
J Dent Res; 1989 Mar; 68(3):472-5. PubMed ID: 2537858
[TBL] [Abstract][Full Text] [Related]
20. Preinfection prophylaxis with herpes simplex virus glycoprotein immunogens: factors influencing efficacy.
Stanberry LR; Myers MG; Stephanopoulos DE; Burke RL
J Gen Virol; 1989 Dec; 70 ( Pt 12)():3177-85. PubMed ID: 2558156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
